SHANGHAI, Jan. 10 /PRNewswire-Asia/ -- WuXi AppTec Inc. today announced
that it has entered into a partnership with QIAGEN to provide an integrated
single solution for molecular biomarker development, validation and
personalized healthcare targets to their respective client bases. QIAGEN will
provide a complete portfolio of instrumentation, training, and consumables and
WuXi AppTec will provide laboratory facilities and staff to execute the
services. The laboratory will be located at WuXi AppTec's campus in Shanghai
and will begin operating immediately.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
Under the terms of the partnership agreement, WuXi AppTec will also work
with QIAGEN to help develop biomarkers, assay panels, personalized healthcare
diagnostics, and other products that QIAGEN intends to bring to market. WuXi
AppTec will use QIAGEN's technologies for a broad range of applications in
support of drug discovery and development on behalf of the company's and
QIAGEN's customers. WuXi AppTec and QIAGEN will also co-promote each other's
services to their respective customers. Both companies are working closely to
identify additional opportunities to deepen their relationship.
"WuXi AppTec has long been interested in partnering with a premier
international molecular biotechnology company like QIAGEN to support the
development of our biomarker business," said Dr. Ge Li, Chairman and CEO of
WuXi AppTec. "This partnership gives us access to innovative technologies and
processes that will allow us to better serve our customers."
"We are very pleased to have entered into this partnership with WuXi
AppTec, a global leader in providing integrated research and development
services to the pharmaceutical industry," said Dr. Victor Shi, President,
Asia Pacific of QIAGEN. "In doing so, we have created what we believe to be
the first laboratory of its kind in Asia equipped with a standardized, fully
integrated, automated sample and assay technology platform for drug discovery
and development and molecular diagnostics in personalized healthcare and other
areas. We believe that this partnership is a significant milestone in
providing high-quality and complete automated solutions for the molecular
biomarker testing industry."
About WuXi AppTec:
WuXi AppTec is a leading pharmaceutical, biotechnology, and medical-device
R&D outsourcing company, with operations in China and the United States. As a
research-driven and customer-focused company, WuXi AppTec provides a broad and
integrated portfolio of laboratory and manufacturing services throughout the
pharmaceutical and medical-device R&D process. WuXi AppTec's services are
designed to help its global partners to improve the success, shorten the time,
and reduce the cost of research and development.
Web: http://www.wuxiapptec.com .
QIAGEN N.V., a Netherlands holding company, is the leading global provider
of sample and assay technologies. Sample technologies are used to isolate and
process DNA, RNA, and proteins from biological samples such as blood or tissue.
Assay technologies are used to make such isolated bio-molecules visible.
QIAGEN has developed and markets more than 500 sample and assay products as
well as automated solutions for such consumables. The company provides its
products to molecular diagnostics laboratories, academic researchers,
pharmaceutical and biotechnology companies, and applied testing customers for
purposes such as forensics, animal or food testing, and pharmaceutical process
control. QIAGEN's assay technologies include one of the broadest panels of
molecular diagnostic tests available worldwide. This panel includes the
digeneHPV Test, which is regarded as a "gold standard" in testing for high-
risk types of human papillomavirus (HPV), the primary cause of cervical cancer,
as well as a broad suite of solutions for infectious disease testing and
companion diagnostics. QIAGEN employs more than 3,400 people in over 30
locations worldwide. Further information about QIAGEN can be found at
For further information, please contact:
WuXi AppTec Inc.
Director of Investor Relations
SOURCE WuXi AppTec Inc.